

# Rheumatoid Arthritis and Coronary Artery Disease: Genetic Analyses Do Not Support a Causal Relation

Henning Jansen, Christina Willenborg, Wolfgang Lieb, Lingyao Zeng, Paola Gloria Ferrario, Christina Loley, Inke R. König, Jeanette Erdmann, Nilesh J. Samani, Heribert Schunkert, and the CARDIoGRAM Consortium

**ABSTRACT. Objective.** Inflammatory diseases, specifically rheumatoid arthritis (RA), are assumed to increase the risk of coronary artery disease (CAD). More recently, multiple single-nucleotide polymorphisms (SNP) associated with RA risk were identified. If causal mechanisms affecting risks of RA and CAD are overlapping, risk alleles for RA might also increase the risk of CAD.

**Methods.** Sixty-one SNP associating with RA in genome-wide significant analyses were tested for association with CAD in CARDIoGRAM (Coronary ARtery Disease Genome wide Replication and Meta-analysis), a metaanalysis including genome-wide association data (22,233 CAD cases, 64,762 controls). In parallel, a set of SNP being associated with low-density lipoprotein cholesterol (LDL-C) was tested as a positive control.

**Results.** Twenty-nine RA-associated SNP displayed a directionality-consistent association with CAD (OR range 1.002–1.073), whereas 32 RA-associated SNP were not associated with CAD (OR range 0.96–0.99 per RA risk-increasing allele). The proportion (48%) of directionality-consistent associated SNP equaled the proportion expected by chance (50%,  $p = 0.09$ ). Of only 5 RA-associated SNP showing  $p$  values for CAD  $< 0.05$ , 4 loci (C5orf30, IL-6R, PTPN22, and RAD51B) showed directionality-consistent effects on CAD, and 1 (rs10774624, locus SH2B3) reached study-wide significance ( $p = 7.29E-06$ ). By contrast, and as a proof of concept, 46 (74%) out of 62 LDL-C-associated SNP displayed a directionality-consistent association with CAD, a proportion that was significantly different from 50% ( $p = 5.9E-05$ ).

**Conclusion.** We found no evidence that RA-associated SNP as a group are associated with CAD. Even though we were not able to study potential effects of all genetic variants individually, shared nongenetic factors may more plausibly explain the observed coincidence of the 2 conditions. (First Release October 15 2016; J Rheumatol 2017;44; 4–10; doi:10.3899/jrheum.151444)

## Key Indexing Terms:

RHEUMATOID ARTHRITIS

SINGLE-NUCLEOTIDE POLYMORPHISMS

CORONARY ARTERY DISEASE

Inflammation is involved in the pathophysiology of coronary artery disease (CAD)<sup>1</sup>. Interestingly, primarily inflammatory diseases such as rheumatoid arthritis (RA) or systemic lupus erythematosus have been found to be associated with a markedly enhanced risk of CAD<sup>2,3</sup>. For example, in 1 study the risk of being affected by CAD was 3-fold higher in

women with RA compared with controls<sup>4</sup>. Moreover, patients with RA showed a prevalence of subclinical femoral atherosclerosis comparable to patients with diabetes<sup>5</sup>, indicating that RA may be an additional independent factor for the development of atherosclerotic diseases. Further, epidemiological studies have reported that RA increases cardiovascular (CV)

From the Deutsches Herzzentrum München and DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Technische Universität München, Munich; Institut für integrative und experimentelle Genomik, Universität zu Lübeck, DZHK, partner site Hamburg/Kiel/Lübeck; Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, DZHK, partner site Hamburg/Kiel/Lübeck, Lübeck; Institut für Epidemiologie, Christian-Albrechts Universität zu Kiel, Kiel, Germany; Department of Cardiovascular Sciences, University of Leicester; Leicester National Institute for Health Research (NIHR) Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, UK.

H. Jansen, MD, Deutsches Herzzentrum München and DZHK, partner site Munich Heart Alliance, Technische Universität München; C. Willenborg, PhD, Institut für integrative und experimentelle Genomik, Universität zu Lübeck, DZHK, partner site Hamburg/Kiel/Lübeck; W. Lieb, MD, Institut für Epidemiologie, Christian-Albrechts Universität zu Kiel; L. Zeng, PhD, Deutsches Herzzentrum München and DZHK, partner site Munich Heart

Alliance, Technische Universität München; P.G. Ferrario, PhD, Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, DZHK, partner site Hamburg/Kiel/Lübeck; C. Loley, PhD, Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, DZHK, partner site Hamburg/Kiel/Lübeck; I.R. König, PhD, Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, DZHK, partner site Hamburg/Kiel/Lübeck; J. Erdmann, PhD, Institut für integrative und experimentelle Genomik, Universität zu Lübeck, DZHK, partner site Hamburg/Kiel/Lübeck; N.J. Samani, MD, Department of Cardiovascular Sciences, University of Leicester, and the Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital; H. Schunkert, MD, Deutsches Herzzentrum München and DZHK, partner site Munich Heart Alliance, Technische Universität München.

Address correspondence to Dr. H. Jansen, Deutsches Herzzentrum München, Technische Universität München, Lazarettstr. 36, 80636 Munich, Germany. E-mail: henning.jansen@gmx.de

Accepted for publication September 9, 2016.

mortality<sup>6,7</sup>. In autopsy studies, patients with RA showed more vulnerable plaques and more inflammation in the coronary artery walls, but a less severe plaque burden compared with controls<sup>8</sup>. Coronary spasm and changes of endothelial function were subsequently discussed to affect cardiac outcome rather than coronary obstruction<sup>9</sup>.

More recently, substantial information has been generated on genetic factors contributing to the complex nature of RA. Based on genome-wide association data, multiple single-nucleotide polymorphisms (SNP) have been reported to be associated with RA at a genome-wide significance level<sup>10,11,12,13,14,15,16,17</sup>. Despite the epidemiological and pathophysiological evidence for an association of RA with CAD, there is still uncertainty whether genetically mediated mechanisms that increased the risk for RA also affect the risk of CAD<sup>3</sup>.

In our present analysis, we assessed whether RA and CAD have overlapping genetic roots by testing whether RA-associated SNP are also associated with an increased risk of CAD. We performed our analyses in the CARDIoGRAM (Coronary ARtery DIsease Genome wide Replication and Meta-analysis) dataset, which includes genome-wide association data from 22,233 patients with CAD and 64,762 population-based controls<sup>18</sup>.

## MATERIALS AND METHODS

**Study sample.** The CARDIoGRAM consortium combined genome-wide association data on CAD cases and controls from 14 patient-based and population-based studies and consortia in a large metaanalysis: Cohorts for Heart and Aging Research in Genomic Epidemiology<sup>19</sup>, CADomics, Atherosclerotic Disease Vascular function and genetic Epidemiology study<sup>20</sup>, deCODE CAD study<sup>21</sup>, Ludwigshafen Risk and Cardiovascular Health Study<sup>22</sup>/AtheroRemo 1 and 2, Myocardial Infarction Genetics Consortium<sup>23</sup>, MedStar<sup>24</sup>, Ottawa Heart Genomics Study<sup>25</sup>, PennCATH<sup>24</sup>, the Wellcome Trust Case Control Consortium (WTCCC)<sup>26</sup>, and the German Myocardial Infarction Family Studies (GerMIFS) I, II, and III<sup>26,27,28</sup>. The protocol of each participating study was approved by their local ethics committees. In addition, our current analyses were approved by the ethics committee of the Technical University of Munich (ID 29516). The main findings of our metaanalysis have been reported elsewhere<sup>29</sup>. In brief, using data from 22,233 CAD cases and 64,762 controls, our analysis identified 25 loci to be genome-wide significantly associated with CAD. Risk alleles at these 25 loci increased CAD risk by 6% to 17%. A detailed description of the main results and individuals (cases/controls) in the participating studies is presented in the supplementary data (Supplementary Table 1 and Supplementary Table 2, available from the authors on request).

The statistical analysis plan for the metaanalyses of the CARDIoGRAM consortium has been described elsewhere in detail<sup>18</sup>. In brief, the associations between SNP and CAD were tested within each study group using a logistic regression model adjusting for age, sex, and potential population stratification, assuming an additive genetic model, which is often used in genome-wide association study (GWAS) settings analyzing common diseases. Then a metaanalysis was performed based on the study-specific effect estimates and their standard errors, and using random-effects or fixed-effects models depending on heterogeneity between the studies. Observed associations between RA SNP and CAD are reported as OR and their 95% CI.

**SNP selection.** Genetic variants associated with RA in whites were identified using the GWAS catalogue from the National Human Genome Research Institute ([www.genome.gov/gwastudies](http://www.genome.gov/gwastudies)) and were also reported by Eyre, *et al*<sup>16</sup>.

In the current literature, we identified 65 SNP displaying association with RA on a genome-wide significant level<sup>10,11,12,13,14,15,16,17</sup>. For SNP that were not available or did not pass quality control in CARDIoGRAM, we identified proxy SNP. We searched for proxies with an  $R^2$ -threshold of 0.8 or higher and a maximal distance of 500 kb. The identified proxy SNP were then tested for association with CAD in CARDIoGRAM. Four SNP of the initially identified variants were not represented in CARDIoGRAM and we could not find appropriate proxies. In total, we integrated 61 genetic variants in our analysis. In secondary analyses, we excluded 38 RA-associated SNP with potential pleiotropic effects on other CAD risk factors (e.g., diabetes, triglycerides, blood pressure, high-density lipoprotein, other inflammatory conditions; Supplementary Table 3, available from the authors on request) and repeated the association analyses with CAD with the remaining RA-associated SNP. Finally, we restricted our analysis to a CARDIoGRAM subgroup containing only women (6579 cases and 23,770 controls) because women are more often affected by RA<sup>30</sup>. By doing so, we intended to see whether the association between genetic variants and CAD was different between men and women (effect modification by sex).

For our proof-of-concept analysis, we tested 62 SNP known to associate with low-density lipoprotein cholesterol (LDL-C) at a genome-wide significance level<sup>31,32</sup> for their association with CAD.

Moreover, we searched the literature for non-HLA SNP, which have been associated with RA disease severity in recent reports<sup>33,34,35</sup>, and subsequently tested these for its association with CAD.

**Statistical methods.** First, we assessed the proportion of RA-associated SNP that displayed a directionality-consistent association with CAD (CAD OR > 1 per RA risk-increasing allele, irrespective of statistical significance of the individual SNP). If RA represented a causal risk factor for CAD, we expected the proportion of RA risk-increasing alleles, which were also positively associated with CAD, to be significantly greater than 50%. This hypothesis was assessed using an exact binomial test. Second, we compared the observed effects of RA-associated SNP on CAD (observed in CARDIoGRAM) to the expected effects of these SNP on CAD. The published OR for CAD in patients with RA ranged from 1.6 to 2.0<sup>36,37,38</sup>, with the largest population-based sample revealing an OR of 1.6. Given such an OR for the association of RA to CAD on the one hand and the respective effect of each SNP on RA on the other hand, we calculated the expected effects of RA SNP on CAD.

**Risk score calculation.** In addition to this approach, we tested whether the risk allele distribution of 61 RA-associated SNP differed between CAD cases and controls. To this end, we used individual level genotypes of 7 European studies (GerMIFS I–V, WTCCC-CAD, and Cardiogenics)<sup>26,27,28,29</sup> with a total of 8542 CAD cases and 10,273 controls and calculated a genetic risk score as follows: for each individual we modeled the 61 SNP as a multilocus genetic risk score by summing the number of risk alleles (0/1/2) for each of the SNP, weighted by their estimated RA effect sizes as reported in the literature. We performed a simple Student t test to compare the differences of the weighted risk score between CAD cases and controls in each study, and then calculated a combined p value by a weighted Z score based on sample size.

## RESULTS

**Association of RA-associated SNP with CAD.** Of the 61 analyzed RA SNP, about half (n = 29) showed an OR > 1 for prevalent CAD in CARDIoGRAM (OR range 1.002–1.073), whereas the other RA-associated SNP (n = 32) displayed an OR < 1 (OR range 0.96–0.99; Figure 1). Thus, this distribution was not different from that expected by chance (50%, p = 0.09).

Four SNP within the loci of C5orf30, SH2B3, IL-6R, and PTPN22 showed directionality-consistent effects on CAD and had p values < 0.05. The SNP (rs10774624,




Figure 1. Genes and respective lead SNP (rs numbers) are listed. Forest plots display the associations of RA associated SNP with CAD in CARDIoGRAM. Boxes represent the OR and whiskers 95% CI. SNP: single-nucleotide polymorphism; RA: rheumatoid arthritis; CAD: coronary artery disease.

$p = 7.29\text{E-}06$ ) at the SH2B3 locus also reached study-wide significance ( $p = 0.05 \div 61 = 0.0008$ ). One SNP (rs2208397) within RAD51B had a  $p$  value  $< 0.05$  (without Bonferroni correction), but the risk alleles were not the same for RA and CAD.

**Secondary analyses.** After removing all SNP with potential effects on traditional CAD risk factors ( $n = 37$ ), the results did not change remarkably. Eleven out of 24 SNP (46%) produced OR greater than 1, while the remaining 13 SNP had

CAD OR below 1 (54%,  $p = 0.15$ ). Only 1 SNP (rs26232 at the C5orf30 locus) remained, showing directionality-consistent effects on CAD with a nominally (not study-wide) significant  $p$  value ( $p = 0.02$ ; Supplementary Figure 1, available from the authors on request).

Because RA is more prevalent among women<sup>30</sup>, we performed an analysis only in women in CARDIoGRAM (6579 cases and 23,770 controls). Out of 57 SNP available, 24/57 SNP (42%) displayed directionality-consistent effects

on CAD and RA ( $p = 0.052$ ). None of the SNP produced a  $p$  value  $< 0.05$  (Supplementary Figure 2, available from the authors on request).

**Comparison of expected and observed effects of RA-associated SNP on CAD.** We calculated the expected effects of RA-related SNP on CAD risk using an assumed effect size ( $\beta$ ) of 0.47 of RA on CAD<sup>38</sup>. The expected OR ranged from 1.04 to 1.51 (Figure 2). We found that the observed effects on CAD (range 0.962–1.073) differed statistically significantly ( $p = 4.9\text{e-}13$ ) from the expected effects.

**Association of LDL-C-associated SNP with CAD.** As a positive control for our methodological approach, we assessed the association of LDL-C-associated genetic variants (thus, variants that were associated with an established causal risk factor for CAD) for association with CAD<sup>31,32</sup>. As expected, most LDL-C-increasing alleles ( $n = 46$  of  $n = 62$ , 74%) displayed a positive association with CAD (a proportion that differed statistically significantly from the 50% expected by chance,  $p = 5.9\text{E-}05$ ; Supplementary Figure 3, available from the authors on request).

**Weighted genetic risk score.** Using individual-level data from a total of 8542 CAD cases and 10,273 controls, we assessed whether the distribution of RA-associated risk alleles differed between CAD cases and controls. The mean genetic RA score in CAD cases (8.37) was not statistically different from the mean score in controls (8.35,  $p = 0.26$ ).


**SNP associated with RA disease severity.** In total, we identified 19 SNP in more recent reports, which have been associated with radiographic disease progression. For 7 SNP,

conflicting results regarding the effect allele exist. Hence, we tested a set of 12 SNP, of which 9 SNP produced  $\text{OR} > 1$  ( $p = 0.05$  using an exact binomial test). One of these SNP (rs1528873) at the DKK-1 locus was associated nominally significantly with CAD risk with directionality-consistent effects (Supplementary Table 4, available from the authors on request).

## DISCUSSION

Using data from 22,233 patients with CAD and 64,762 controls, we assessed the association of RA-related SNP with CAD. We found no evidence for a statistically significant association of RA SNP with CAD risk. About half of the RA-associated SNP ( $n = 29$ , 48%) displayed CAD OR greater than 1, while the other half ( $n = 32$  SNP) produced OR below 1 for the association with CAD in our dataset, a distribution as expected by chance. There was, however, one remarkable exception. An SNP (rs10774624) at the SH2B3 locus showed directionality-consistent effects on CAD and reached study-wide significance ( $p = 7.29\text{E-}06$ ). Indeed, associations between the SH2B3 locus and CAD have been reported previously<sup>29</sup>. However, this effect is possibly driven by pleiotropic effects on, for example, blood pressure or Type 1 diabetes<sup>39,40</sup>. In line with this notion, the encoded protein of this locus (SH2B adaptor protein 3) has been found to enhance inflammation and affect the vascular biology and homeostasis by complex intracellular signaling pathways<sup>41</sup>.

After removing all SNP with potential effects on CV risk factors, the results did not change substantially. Similarly, restricting our analysis to women did not affect the results.



**Figure 2.** Bar plot comparing the predicted and observed effects on CAD. The predicted effects are calculated based on the respective SNP effects on RA and the effect of RA on CAD coming from epidemiological data. The observed effects were derived from the CARDIoGRAM dataset. CAD: coronary artery disease; SNP: single-nucleotide polymorphism; RA: rheumatoid arthritis.



In addition, the burden of RA risk alleles (expressed as a weighted genetic risk score or RA) was not different between CAD cases and controls. As a proof of principle, we analyzed 62 genetic variants associated with LDL-C — a causal risk factor for CAD — in the same fashion. As expected, most SNP (46/62, 74%) displayed a positive association with CAD.

The clinical association between RA and CAD has been recognized in many prior studies<sup>4</sup>. Compared with healthy individuals, patients with RA have an increased risk of dying from CV causes<sup>42</sup>, have an increased risk of clinical CVD events (such as CAD<sup>42</sup> and stroke<sup>43</sup>), and present more often with subclinical CV disease (CVD) manifestations, as indicated, e.g., by an altered pulse wave velocity, increased carotid intima-media thickness (IMT), and lower flow-mediated dilatation as compared with controls (reviewed<sup>44</sup>). Guidelines, therefore, suggest to screen patients with RA for CAD and subclinical vascular pathologies and to treat them early and aggressively once atherosclerosis is detected<sup>45</sup>.

However, whether RA actually causes CAD has not been proven. Prior genetic analyses evaluated defined genetic variation as independent risk factors for CV events in patients with RA. For example, CD40, which acts as a key player of the inflammation process initiation, carries SNP at its locus that have been found to associate with RA itself and with carotid IMT, a marker for subclinical CVD, in patients with RA<sup>46</sup>. Further, genetic variants of the interferon regulatory factor 5 were found to be associated with an increased risk of CV events in patients with RA<sup>47</sup>.

In our larger dataset, we found no supporting evidence for an association of genetic variants at the above-mentioned individual loci with CAD risk.

We expanded on these analyses by using large genome-wide datasets to assess whether risk alleles that are associated with an increased risk for RA are also associated with CAD risk. The underlying concept is that if RA is causally related to CAD, RA-related alleles would also translate into observable increases in CAD risk. However, in our large dataset including 22,233 CAD cases and 64,762 controls, we found no such evidence.

As an alternative explanation for the greater CV risk in patients with RA, a greater burden with traditional risk factors among patients with RA<sup>48</sup> has been emphasized by many authors. Indeed, arterial hypertension and unfavorable lipid profiles have been found to be more prevalent in patients with RA than in controls<sup>49</sup>. Other reports provided some evidence that the increased CVD risk could be because of side effects of RA medication. In particular, the common use of nonsteroidal antiinflammatory drugs, cyclooxygenase-2 inhibitors, and oral glucocorticoids has been shown to significantly increase systolic blood pressure, which might subsequently result in a higher risk of CVD<sup>50</sup>. Despite the evidence for an increased prevalence of traditional risk factors in patients with RA, some authors argue that tradi-

tional factors even in accumulation are not able to fully explain the increased risk of CAD<sup>46</sup>. In this regard, an underlying inflammatory background linking RA and CAD has been frequently pronounced. This concept is supported by growing evidence of reduced CV risk, associated with using antiinflammatory agents such as methotrexate or biologicals such as antitumor necrosis factor- $\alpha$ <sup>46</sup>.

Another observation deserves some consideration. The incidence of CAD in patients with RA may be influenced by the presence of anticitrullinated peptide antibodies (ACPA): studies reported a higher risk of CAD in ACPA-positive patients compared with ACPA-negative patients with RA<sup>51</sup>. Interestingly, the genetic background of these 2 RA subtypes shows a remarkable difference. While the specific HLA-DRB1 alleles are commonly found in ACPA-positive patients, ACPA-negative patients often lack this important genetic risk factor<sup>52,53</sup>. Overall, however, ACPA-negative and ACPA-positive RA share a large proportion of the reported susceptibility loci<sup>54</sup>. Hence, we do not feel that this specific difference has influenced our principal findings.

SNP associating with RA susceptibility produced a null finding in our overall dataset. Interestingly, previous reports have shown that many SNP that are associated with the risk of contracting RA are not necessarily associated with disease severity<sup>35</sup>.

We therefore specifically studied SNP known to associate with disease severity and observed a trend for a positive association with CAD risk in CARDIoGRAM (9 out of 12 SNP produced OR > 1). Only susceptibility variants in the HLA region were associated with both disease susceptibility and severity in several analyses<sup>33</sup>. By contrast, non-HLA variants did not produce such significant results in radiographic disease progression<sup>33</sup>. Our data indeed indicate that SNP that are associated with the risk of developing RA are not associated with CAD. However, SNP that are associated with greater inflammatory activity in patients with RA (more severe disease activity) provided some evidence of association with CAD in CARDIoGRAM, underscoring the concept that it is rather the inflammatory burden associated with (increased) RA disease activity that predisposes to CAD than the RA disease per se.

*Strengths and limitations.* The large and genome-wide dataset of CARDIoGRAM allowed us to assess many ( $n = 61$ ) SNP for their association with CAD that have previously been identified to associate with RA at a genome-wide significant level. The following limitations merit consideration. First, 4 RA SNP did not pass quality control in CARDIoGRAM and we did not find appropriate proxy SNP. Although very unlikely, data from these missing SNP could have theoretically altered our conclusions. Second, we were not able to study the relation of RA-associated SNP with clinical RA in our dataset. Third, based on a reported prevalence of 0.8% in the general adult population<sup>55</sup>, about 700 participating individuals in CARDIoGRAM might be affected by RA.

Fourth, many studies contributing to CARDIoGRAM included younger patients with myocardial infarction and CAD only. Hence, the effect of RA on CAD might not have been identified adequately in these individuals because RA might act as a risk factor for CAD rather later in life. Fifth, it is possible that some RA-associated SNP exert unknown pleiotropic effects on intermediate CV phenotypes and thereby influence (neutralize) the risk of CAD. However, given the large number of SNP studied, it is unlikely that a systematic effect by these SNP on CAD might have altered our results significantly. Sixth, while designing the CARDIoGRAM database, many individual SNP of the HLA region were not considered. Not surprisingly, about two-thirds of individual HLA-DRB variants identified to associate with RA risk in GWAS ( $p < 5 \times 10^{-8}$ ) were not represented in CARDIoGRAM. Therefore, we used rs9268839 as 1 significant representative in our analysis.

Taken together, our data provide no evidence for a causal association of RA with CAD risk. Together with a shared inflammatory background of CAD and RA, traditional risk factors might explain the increased prevalence of CAD in patients with RA more than a common genetic architecture.

## APPENDIX 1.

List of study collaborators. Members of the CARDIoGRAM Consortium: Sekar Kathiresan, Muredach P. Reilly, Nilesh J. Samani, Heribert Schunkert, Jeanette Erdmann, Themistocles L. Assimes, Eric Boerwinkle, Alistair Hall, Christian Hengstenberg, Inke R. König, Reijo Laaksonen, Ruth McPherson, John R. Thompson, Unnur Thorsteinsdottir, Andreas Ziegler, Devin Absher, Li Chen, L. Adrienne Cupples, Eran Halperin, Mingyao Li, Kiran Musunuru, Michael Preuss, Arne Schillert, Gudmar Thorleifsson, Benjamin F. Voight, George A. Wells, Panos Deloukas, Hilma Holm, Robert Roberts, and Alexandre F.R. Stewart.

## REFERENCES

- Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med* 1999;340:115–26.
- Kaul MS, Rao SV, Shaw LK, Honeycutt E, Ardoin SP, St Clair EW. Association of systemic lupus erythematosus with angiographically defined coronary artery disease: a retrospective cohort study. *Arthritis Care Res* 2013;65:266–73.
- Ong KL, Wu BJ, Cheung BM, Barter PJ, Rye KA. Arthritis: its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008. *Ann Epidemiol* 2013;23:80–6.
- Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. *Circulation* 2003;107:1303–7.
- Protogerou A, Zampeli E, Tentolouris N, Makrilakis K, Kitas G, Sfrikakis PP. Subclinical femoral atheromatosis in rheumatoid arthritis: comparable prevalence to diabetes mellitus in a case-control study. *Ann Rheum Dis* 2012;71:1534–6.
- Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. *Arthritis Rheum* 1994;37:481–94.
- Kleinert S, Krueger K. [Cardiovascular comorbidity and its risk factors in rheumatoid arthritis]. [Article in German] *Z Rheumatol* 2011;70:464–72.
- Aubry MC, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. *J Rheumatol* 2007;34:937–42.
- Gasparyan AY, Cocco G, Pandolfi S. Cardiac complications in rheumatoid arthritis in the absence of occlusive coronary pathology. *Rheumatol Int* 2012;32:461–4.
- Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat Genet* 2010;42:508–14.
- Gregersen PK, Amos CI, Lee AT, Lu Y, Remmers EF, Kastner DL, et al. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. *Nat Genet* 2009;41:820–3.
- Orozco G, Viatte S, Bowes J, Martin P, Wilson AG, Morgan AW, et al; UK Rheumatoid Arthritis Genetics Consortium; Wellcome Trust Case Control Consortium; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Consortium. Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association study. *Arthritis Rheumatol* 2014;66:24–30.
- Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, Burtt NP, et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. *Nat Genet* 2008;40:1216–23.
- Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis—a genome-wide study. *N Engl J Med* 2007;357:1199–209.
- Eleftherohorinou H, Hoggart CJ, Wright VJ, Levin M, Coin LJ. Pathway-driven gene stability selection of two rheumatoid arthritis GWAS identifies and validates new susceptibility genes in receptor mediated signalling pathways. *Hum Mol Genet* 2011;20:3494–506.
- Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, et al; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate; Wellcome Trust Case Control Consortium. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. *Nat Genet* 2012;44:1336–40.
- Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al; RACI consortium; GARNET consortium. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature* 2014;506:376–81.
- Preuss M, König IR, Thompson JR, Erdmann J, Absher D, Assimes TL, et al. Design of the Coronary ARtery Disease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: a genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. *Circ Cardiovasc Genet* 2010;3:475–83.
- Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JJ, et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: design of prospective meta-analyses of genome-wide association studies from 5 cohorts. *Circ Cardiovasc Genet* 2009;2:73–80.
- Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, Tang H, et al. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. *Hum Mol Genet* 2008;17:2320–8.
- Helgadóttir A, Thorleifsson G, Manolescu A, Gretarsdóttir S, Blondal T, Jonasdóttir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. *Science* 2007;316:1491–3.
- Winkelmann BR, März W, Boehm BO, Zotz R, Hager J, Hellstern P, et al; LURIC Study Group (LUDwigshafen Risk and Cardiovascular Health). Rationale and design of the LURIC study—a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. *Pharmacogenomics* 2001;2 Suppl 1:S1–73.
- Myocardial Infarction Genetics Consortium, Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nat Genet* 2009;41:334–41.

24. Lehrke M, Millington SC, Lefterova M, Cumaranatunge RG, Szapary P, Wilensky R, et al. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. *J Am Coll Cardiol* 2007;49:442–9.
25. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. *Science* 2007;316:1488–91.
26. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 2007;447:661–78.
27. Erdmann J, Grosshennig A, Braund PS, König IR, Hengstenberg C, Hall AS, et al; Italian Atherosclerosis, Thrombosis, and Vascular Biology Working Group; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium; Cardiogenics Consortium. New susceptibility locus for coronary artery disease on chromosome 3q22.3. *Nat Genet* 2009;41:280–2.
28. Erdmann J, Willenborg C, Nahrstaedt J, Preuss M, König IR, Baumert J, et al. Genome-wide association study identifies a new locus for coronary artery disease on chromosome 10p11.23. *Eur Heart J* 2011;32:158–68.
29. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al; Cardiogenics; CARDIoGRAM Consortium. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet* 2011;43:333–8.
30. Charles J, Britt H, Pan Y. Rheumatoid arthritis. *Aust Fam Physician* 2013;42:765.
31. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* 2010;466:707–13.
32. Global Lipids Genetics Consortium, Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet* 2013;45:1274–83.
33. Scott IC, Rijsdijk F, Walker J, Quist J, Spain SL, Tan R, et al. Do genetic susceptibility variants associate with disease severity in early active rheumatoid arthritis? *J Rheumatol* 2015;42:1131–40.
34. de Rooy DP, Tsonaka R, Andersson ML, Forslind K, Zhernakova A, Frank-Bertoncelj M, et al. Genetic factors for the severity of ACPA-negative rheumatoid arthritis in 2 cohorts of early disease: a genome-wide study. *J Rheumatol* 2015;42:1383–91.
35. Krabben A, Huizinga TW, Mil AH. Biomarkers for radiographic progression in rheumatoid arthritis. *Curr Pharm Des* 2015; 21:147–69.
36. Crowson CS, Liao KP, Davis JM 3rd, Solomon DH, Matteson EL, Knutson KL, et al. Rheumatoid arthritis and cardiovascular disease. *Am Heart J* 2013;166:622–8.e1.
37. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. *Arthritis Rheum* 2005;52:402–11.
38. Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid arthritis. *Ann Rheum Dis* 2006;65:1608–12.
39. Plagnol V, Howson JM, Smyth DJ, Walker N, Hafler JP, Wallace C, et al; Type 1 Diabetes Genetics Consortium. Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. *PLoS Genet* 2011;7:e1002216.
40. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. *Nat Genet* 2009;41:677–87.
41. Devallière J, Charreau B. The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling. *Biochem Pharmacol* 2011;82:1391–402.
42. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Arthritis Rheum* 2008;59:1690–7.
43. Zha AM, Di Napoli M, Behrouz R. Prevention of stroke in rheumatoid arthritis. *Curr Neurol Neurosci Rep* 2015;15:77.
44. van Breukelen-van der Stoep DF, Klop B, van Zeven D, Hazes JM, Castro Cabezas M. Cardiovascular risk in rheumatoid arthritis: how to lower the risk? *Atherosclerosis* 2013;231:163–72.
45. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. *Ann Rheum Dis* 2010;69:325–31.
46. García-Bermúdez M, González-Juanatey C, López-Mejías R, Teruel M, Corrales A, Miranda-Filloo JA, et al. Study of association of CD40-CD154 gene polymorphisms with disease susceptibility and cardiovascular risk in Spanish rheumatoid arthritis patients. *PLoS One* 2012;7:e49214.
47. García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, Llorca J, González-Juanatey C, et al. Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis. *Arthritis Res Ther* 2014;16:R146.
48. Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? *Ann Rheum Dis* 2008;67:64–9.
49. Chung CP, Giles JT, Petri M, Szklo M, Post W, Blumenthal RS, et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. *Semin Arthritis Rheum* 2012;41:535–44.
50. Panoulas VF, Metsios GS, Pace AV, John H, Treharne GJ, Banks MJ, et al. Hypertension in rheumatoid arthritis. *Rheumatology* 2008;47:1286–98.
51. Farragher TM, Goodson NJ, Naseem H, Silman AJ, Thomson W, Symmons D, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. *Arthritis Rheum* 2008;58:359–69.
52. Padyukov L, Seielstad M, Ong RT, Ding B, Rönnelid J, Seddighzadeh M, et al; Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study group. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. *Ann Rheum Dis* 2011;70:259–65.
53. de Vries RR, van der Woude D, Houwing JJ, Toes RE. Genetics of ACPA-positive rheumatoid arthritis: the beginning of the end? *Ann Rheum Dis* 2011;70 Suppl 1:i51–4.
54. Terao C, Ohmura K, Kochi Y, Ikari K, Okada Y, Shimizu M, et al. Anti-citrullinated peptide/protein antibody (ACPA)-negative RA shares a large proportion of susceptibility loci with ACPA-positive RA: a meta-analysis of genome-wide association study in a Japanese population. *Arthritis Res Ther* 2015;17:104.
55. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. *Rheumatology* 2002;41:793–800.